A randomized trial found that adding chemotherapy to tamoxifen significantly increases disease-free and overall survival rates for postmenopausal women with lymph node-negative, ER-negative breast cancer. In contrast, no survival benefit was observed for those with ER-positive tumors.
Researchers found that adding hormone-suppression therapy to radiotherapy for advanced prostate cancer significantly improved five-year disease-free survival rates. The study involved 415 patients, with those receiving combined therapy showing a substantial increase in overall survival rates.
This study found that paclitaxel- and carboplatin-based regimens can prolong survival of patients with advanced non-small cell lung cancer, with two-year survival rates similar to those achieved at one year with best supportive care. However, three-drug regimens were slightly more toxic and did not provide additional benefits.
A study of 219 patients with non-metastatic colon cancer found that laparoscopy-assisted colectomy (LAC) reduced perioperative morbidity, shortened hospital stays, and prolonged cancer-related survival. LAC was associated with a 60% lower risk of tumour relapse compared to open colectomy.
A multicenter randomized trial found that chemoembolisation significantly improves survival rates compared to conservative treatment, with 82% and 63% survival probabilities at 1 year and 2 years, respectively.
Researchers found that premenopausal women who underwent mastectomy alone had similar survival outcomes regardless of the menstrual cycle phase. In contrast, those who received adjuvant oophorectomy and tamoxifen during the luteal phase experienced better disease-free and overall survival rates. Additionally, studies suggest socioecono...
Researchers have found a combination therapy of lamivudine and hepatitis B immune globulin significantly reduces HBV infection recurrence after liver transplant, with one-year and three-year survival rates of 92% and 81%, respectively. This breakthrough treatment offers hope for patients with chronic HBV cirrhosis.
Researchers found a 16% increased risk of death for blacks compared to whites with comparable treatment, which narrowed to 7% after adjusting for other causes. The disparity was eliminated in most cancers, except for breast and two rare types.
A recent study published in The Lancet found that methotrexate treatment significantly improves survival rates among rheumatoid arthritis patients. By reducing cardiovascular mortality, methotrexate may provide a substantial survival benefit, setting a standard for future disease-modifying antirheumatic drugs.
Systematic review and meta-analysis of 12 randomised trials shows a 6% increase in one-year survival for patients receiving chemotherapy with radiotherapy compared to those receiving radiotherapy alone. Patients also experience a two-month improvement in average survival time.
A recent study found that social factors can significantly affect the survival rates of lung cancer patients, with African Americans facing higher mortality rates due to poorer physical performance and weight loss. The researchers adjusted for these factors in their analysis, finding no difference in outcomes between ethnic groups.
A recent study found that liver transplant patients from African American and Asian backgrounds experience lower two-year and five-year survival rates compared to their white American and Hispanic counterparts. The study suggests a need for further research into the reasons behind these disparities in patient outcomes.
A Hopkins-led study found that African Americans and Asians have poorer graft rejection and survival rates after liver transplantation compared to white Americans and Hispanics. The study's lead author suggests that more research is needed to determine the causes of these disparities, with preliminary data suggesting socioeconomic fact...
A new treatment combining CPT-11 and cisplatin has shown superior results in prolonging survival for patients with small-cell lung cancer. Patients receiving this treatment had a 55% improvement in one-year survival and were four times more likely to be alive at two years.
A new treatment regimen combining chemotherapy and radiation therapy significantly improved failure-free survival rates for patients with early-stage Hodgkin's disease. The study also found that staging laparotomy could be avoided, leading to better patient outcomes.
A statistical analysis of 47 randomized trials involving 18,000 women found that chemotherapy improves survival time adjusted for quality of life for both younger and older women. Younger women treated with chemotherapy gained an average of 10.3 months of relapse-free survival within 10 years.
Patients with lung cancer who undergo lung resection surgery at high-volume hospitals experience significantly better outcomes, including higher five-year survival rates (44%) compared to low-volume hospitals (33%). Complication rates are also reduced in high-volume facilities.
Researchers found that survival rates for primary eye cancer treatments are essentially the same, with a five-year survival rate of 82% for both radiation therapy and eye removal. The study's findings expand the capability of doctors to provide accurate diagnoses and state-of-the-art treatments.
A new study reveals that vaccinating poor children against measles significantly improves their long-term survival rates and reduces health inequities. The research found that vaccinated children from poor families were 50% less likely to die before age 5 compared to unvaccinated children.
A study by Dr. Vivek Goel and colleagues found that women with early-stage breast cancer treated in specialized teaching hospitals had a higher 5-year survival rate than those treated in community hospitals. The results suggest that initial treatment at specialized centers may be advantageous for women with small tumors.
Researchers found a 2% survival benefit among patients undergoing colon cancer surgeries at high-volume hospitals compared to lower volume facilities. The study examined over 28,000 Medicare beneficiaries and controlled for age, sex, and cancer stage.
A Phase III study found significant improvements in overall survival, disease-free status, and complete remission rates for patients with aggressive non-Hodgkin's lymphoma treated with MabThera and CHOP chemotherapy. Survival at 1-year was 83% for the rituximab combination therapy group compared to 68% for those receiving CHOP alone.
A definitive study led by John Kirkwood at the University of Pittsburgh Cancer Institute found that high-dose interferon alfa 2b extends both overall survival and relapse-free survival in surgically treated high-risk melanoma patients. This regimen significantly outperforms a comparison vaccine, GMK, in terms of survival impact.
The COPERNICUS trial demonstrates a significant survival benefit of carvedilol in patients with advanced heart failure, reducing mortality rates by 35%. The study involved over 2,200 patients and showed that carvedilol decreased mortality rates compared to placebo.
A recent San Francisco study found that antiretroviral treatment continues to significantly improve AIDS patient survival rates, with a 60% reduction in risk of death for those receiving HAART. The study also revealed increased survival benefits over time, particularly among those diagnosed between 1996 and 1997.
A Phase III study found that a combination of histamine dihydrochloride and lower doses of interleukin-2 improved overall survival, increased survival rates at 12, 18, and 24 months, and reduced time-to-disease-progression compared to IL-2 alone. The treatment was well-tolerated and had substantially less toxicity.
The study confirms that M-Vax increases the survival rate of patients with advanced Stage III melanoma, even after disease recurrence. Patients who developed an immune response against their melanoma had a far better outcome, with a five-year survival rate of 65%.
A Phase III trial shows long-term hormone suppression can control recurrence and improve survival in prostate cancer patients. The treatment significantly reduces disease-free survival, local progression, and freedom from distant metastasis.
Researchers developed an intensive treatment combining radiation and chemotherapy to control locally advanced head and neck cancer, achieving complete local control for 92% of patients. The therapy increased long-term survival to 55%, with most side effects resolving after treatment.
Researchers discovered that high levels of BAG-1 protein correlate with better long-term survival and overall survival rates for women with early breast cancer. The study found a significant difference in 10-year survival rates between women with high and low BAG-1 protein levels.
Patients with heart attacks who are taken directly to high-volume hospitals have a higher survival rate than those treated at smaller centers. Younger patients and those with cardiologists as attending physicians also benefit from increased survival rates.
A study by Duke University researchers found that Medicare patients treated at major teaching hospitals have better survival rates for common conditions like hip fractures, stroke, and coronary heart disease. However, these facilities cost the Medicare program more than non-teaching hospitals.
Researchers at University of Pittsburgh Medical Center found that lung transplant patients who received lungs preserved for more than six hours had similar survival rates compared to those stored for less than four hours. The study, which examined over 350 cases, suggests that the current organ allocation policy may need to be revised.
Researchers identify Hid protein as a key player in preventing programmed cell death, finding it relies on survival signals for regulation. The discovery has potential applications in treating neurodegenerative diseases and conditions like stroke.
A large-scale randomized study found that chemotherapy improves long-term survival for women under 50 and those in their 50s and 60s, even if the cancer has not spread. The treatment also showed benefits for women without evidence of disease spread.
Researchers found that bone marrow transplant significantly improves disease-free survival for children with high-risk neuroblastoma. Additionally, follow-up therapy with high doses of retinoic acid shows promising results, with a three-year event-free survival rate of 55% compared to 16% for those treated with consolidation chemothera...
A 15-year study of 628 AML patients confirms that chromosomal abnormalities can predict treatment success and likelihood of cure. Patients with specific genetic markers tend to have better outcomes, while those without them face poorer survival rates.
A novel surgical technique developed at the UPMC has improved graft survival rates in patients receiving combined pancreas and kidney transplants. The technique protects the pancreas from injury during removal and transport, resulting in higher patient survival rates.
A study of kidney patients found that those taken off steroids had significantly better one- and three-year survival rates compared to those still on the medication. One-year patient survival was 99% in the group no longer taking steroids, while one- and three-year graft survival rates were also higher.
A new clinical trial has shown that combining chemotherapy with radiation therapy can improve the survival rate of patients with nasopharyngeal carcinoma by 31% compared to radiation alone. The treatment, which included cisplatin and 5-fluorouracil, resulted in a three-year survival rate of 76% for those receiving the combination therapy.